Research Fields
Biomarker Discovery
Liquid Biopsy (LBx)
Development of a precision molecular diagnostic platform based on liquid biopsy technology
Our goal is to develop a precision molecular diagnostic platform that enables early diagnosis, prediction of treatment response and personalized therapy establishing a new paradigm in precision medicine through bllod-based non-invasive diagnostics.
Data Science (BI)
Elucidation of disease mechanism through large scale biological data analysis to identify novel therapeutic strategies
We aim to contribute to precision medicine by identifying tumor-driving mutations and understanding tumor evolution using clinical and multi-omics data to develop personalized therapeutic strategies.
Antbody based Therapeutics
Discovery
Discovery of antibodies against diverse targets
Our research focuses on identifying tumor microenvironment–based targets and discovering antibodies using phage display aiming to induce anti-tumor effects through signal blockade and immune activation.
Multispecifics
Development of antibodies targeting multiple antigens simultaneously
Our research focuses on designing and developing multispecific antibodies (bispecific, biparatopic, and trispecific) that simultaneously target multiple antigens to overcome complex disease mechanisms enabling modulation of the tumor microenvironment, activation of immune cells and simultaneous inhibition of signaling pathways.
Immunomodulation
Development of immune checkpoint inhibitors and bispecific antibodies
Our research aims to develop proprietary immune checkpoint inhibitors targeting specific immune cell sub-types to enhance immune activation. We establish intellectual property through sequence and patent analyses and subsequently engineer these antibodies into bispecific formats. Antibodies are produced using CHO-based expression systems and evaluated for functional efficacy. We also investigate diverse immune checkpoint targets within the tumor microenvironment to design subtype-specific targeting strategies for therapeutic development.
New Modality
Engineering of antibody-based Omomyc and asymmetric siRNA therapeutics
Our goal is to improve the delivery of Omomyc and asymmetric siRNA to tumors by conjugating them with antibodies. This approach is expected to increase the specificity of drug delivery reducing off-target effects and inducing apoptosis of cancer cells by targeting MYC protein and other cancer-related genes within the tumor microenvironment.
IFN-β based Therapeutics
Development of immunocytokines
Our research focuses on developing IFN-β–based immunocytokines by conjugating cytokines to antibodies for tumor-specific delivery while employing masking strategies to minimize systemic toxicity and maximize immune activation.
Cell & Gene Therapy
iPSC based CAR-X
Development of allogeneic CAR-X immunotherapies and NK cell therapies using an iPSC-based platform
Our research focuses on the development of genetically engineered CAR-NK cell therapies derived from iPSCs with reduced immune rejection and enhanced functional activity.
Additional Areas
Alzheimer’s Disease
Development of antibody-based therapeutics and identification of early diagnostic biomarkers for Alzheimer’s disease
Our research focuses on enabling early diagnosis of Alzheimer’s disease using blood-based biomarkers and inhibiting disease progression through drug delivery via a BBB penetration platform.
Artificial Intelligence
AI-driven de novo generation of antigen-conditioned antibody sequences
Our research focuses on generating antibody sequences using AI-driven de novo design and optimizing candidates through experimental validation and iterative learning.
In vivo Model
Enhancement of the abscopal effect through phototherapy and investigation of its underlying mechanisms
Our research focuses on tumor-targeted photothermal and photodynamic therapies using photosensitizers to achieve local tumor control and systemic anti-tumor immunity. We investigate the immune mechanisms underlying the abscopal effect and aim to potentiate this response through combination strategies with immunocytokines and immune checkpoint inhibitors.